Welcome to our dedicated page for Fractyl Health news (Ticker: GUTS), a resource for investors and traders seeking the latest updates and insights on Fractyl Health stock.
Fractyl Health, Inc. reports clinical and corporate developments as a clinical-stage metabolic therapeutics company focused on obesity and type 2 diabetes. Its lead product candidate, Revita®, is a minimally invasive endoscopic therapy designed to remodel the duodenal lining for post-GLP-1 weight maintenance; it is investigational in the United States, has FDA Breakthrough Device designation, and is CE marked in the European Union and United Kingdom.
Company news also covers the Rejuva® AAV-based gene therapy platform, including RJVA-001 for type 2 diabetes and RJVA-002 for obesity, as well as clinical data from REMAIN-1, regulatory authorizations, financial results, capital-plan updates and public-company governance changes.
Fractyl Health (NASDAQ: GUTS), a metabolic therapeutics company specializing in treatments for obesity and type 2 diabetes, has scheduled two important investor events. The company will release its Q1 2025 financial results and provide business updates on May 13, 2025, at 4:30 p.m. ET via a live webcast.
Additionally, CEO and Co-Founder Harith Rajagopalan, M.D., Ph.D., will present at the BofA Securities 2025 Health Care Conference on May 14, 2025, at 5:00 p.m. PT. Both events will be accessible through the company's investor relations website, with recordings available for replay after the live presentations.
Fractyl Health (Nasdaq: GUTS) announced an upcoming presentation of preclinical data for their innovative Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting in New Orleans.
Key highlights:
- The presentation focuses on a single-administration therapy targeting obesity and type 2 diabetes root causes
- Research title: "Endoscopic Ultrasound-Guided Delivery of Human Glucagon-like Peptide-1 Pancreatic Gene Therapy: Safety and Feasibility in a Porcine Model"
- Scheduled for May 17, 2025, at 9:15 AM CT in NOLA Theater A
- Part of the AAV Preclinical and Proof-of-Concept Studies session
The presentation materials will be accessible through the Presentations & Publications section of Fractyl's website after the event concludes on May 17, 2025.
Fractyl Health (NASDAQ: GUTS) has reported promising early data from its REVEAL-1 study, suggesting that its Revita® procedure may help prevent weight regain after patients discontinue GLP-1 medications. The study shows that at 1-month post-procedure, 7 patients experienced an average weight regain of just 1.2%, compared to the typical 3% regain observed after GLP-1 discontinuation.
The REVEAL-1 cohort, part of the ongoing REMAIN-1 pivotal study, has treated 15 patients to date, with no safety or tolerability concerns reported. This safety profile aligns with previous data from over 100 treated patients. The company's REMAIN-1 pivotal study is now more than 50% enrolled, with a midpoint data analysis expected in Q3 2025.
Revita, which holds FDA Breakthrough Device designation, is being studied under an open Investigational Device Exemption. The company aims to position it as the first approved intervention specifically for post-GLP-1 weight maintenance, addressing a growing unmet need in obesity treatment.
Fractyl Health (NASDAQ: GUTS) reported its Q4 and full year 2024 financial results, highlighting strong progress in its REMAIN-1 pivotal study for weight maintenance post-GLP-1 therapy. The study has enrolled 189 patients across 13 clinical sites in six months, with midpoint data analysis expected in Q2 2025 and full enrollment by summer 2025.
Key financial metrics for Q4 2024 include:
- R&D expenses increased to $20.3M (vs $10.1M in Q4 2023)
- SG&A expenses rose to $4.9M (vs $2.8M in Q4 2023)
- Net loss widened to $25.0M (vs $19.2M in Q4 2023)
- Cash position of $67.5M as of December 31, 2024
The company plans to submit its first Clinical Trial Application module for RJVA-001 in type 2 diabetes in H1 2025, with preliminary data expected in 2026. Fractyl has strategically focused on weight maintenance and extended its cash runway into 2026.
Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company specializing in treatments for obesity and type 2 diabetes (T2D), has announced it will release its fourth quarter and full year 2024 financial results on March 3, 2025, at 4:30 p.m. ET. The company will also provide business updates during the event.
A live webcast of the conference call will be available in the 'Events' section of Fractyl's investor relations website, with a replay option available after the event.
Fractyl Health (NASDAQ: GUTS) announced strategic changes focusing on two key programs: the Revita® weight maintenance program and Rejuva® pancreatic gene therapy. The company is prioritizing its REMAIN-1 pivotal study for weight maintenance post-GLP-1 withdrawal, with midpoint data analysis expected in Q2 2025 and full enrollment by summer 2025.
Initial results from the REVEAL-1 cohort showed promising outcomes in weight maintenance after GLP-1 discontinuation, with over 145 patients enrolled across 10 clinical sites in 5 months. The company will pause investment in Revita programs for Type 2 Diabetes, including the REVITALIZE-1 study and German Real-World Registry.
The Rejuva gene therapy program has completed key preclinical studies, with first-in-human studies for RJVA-001 planned for H1 2025. To optimize resources, Fractyl is implementing a 17% workforce reduction, extending its cash runway into 2026.